Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (5.199.814 €): Bahnbrechende regulatorische Innovation und Entwicklung durch Sandbox-Umgebungen Hor 01.11.2025 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Bahnbrechende regulatorische Innovation und Entwicklung durch Sandbox-Umgebungen

BRIDGE aims to enhance healthcare innovation in Europe by developing a comprehensive framework for designing and operationalizing regulatory sandboxes. By addressing current regulatory limitations and engaging all stakeholders while ensuring compliance, the project seeks to create adaptable, fit-for-purpose methodologies that strengthen the regulatory ecosystem's capacity to promote healthcare innovation. The project’s objectives include identifying and analysing existing regulatory sandboxes across various domains and maturity levels, to determine how their modules can complement current healthcare regulations. BRIDGE will develop a horizon scanning methodology to continuously identify emerging technologies that challenge existing regulatory systems, analyzing their requirements for potential inclusion in regulatory sandboxes to ensure adaptability within an evolving innovation ecosystem. Through multi-stakeholder consultations, BRIDGE will elaborate and assess case studies, as well as develop operational checklists for module design and evidence packages to guide tailored sandbox launches. The project will also develop the Modular Operational Sandbox for Healthcare Innovation and Compliance (MOSAIC), an architectural model with interconnected modules featuring detailed functional specifications and mapped information flows aligned with specific case studies. Additionally, BRIDGE will engage key stakeholders—including regulatory bodies, industry consortia, HTA bodies, payers, healthcare providers, and patients—in an in-depth analysis, consultation, and consensus-building process to ensure the sandbox approach is comprehensive, functional, and adaptable to future advancements. Finally, the project will deliver comprehensive recommendations for the sandbox methodology’s end-to-end operations, encompassing legal, compliance, policy, and regulatory outputs to provide a robust implementation framework.


Geförderte Unternehmen:

Firmenname Förderungssumme
Eli Lilly and Company Ltd. ?
Academisch Ziekenhuis Groningen 229.894 €
Astellas Pharma Europe B.V. 0,00 €
Biogen Idec Ltd. 0,00 €
Bundesinstitut FUR Arzneimittel UND Medizinprodukte 402.613 €
Charite - Universitaetsmedizin Berlin 228.123 €
CSL Behring GmbH 0,00 €
Eli Lilly AND Company 0,00 €
Empirica Gesellschaft FUR Kommunikations UND Technologieforschung mbH 794.100 €
Euroscan International Network e. V. 473.940 €
F. Hoffmann-LA Roche AG 0,00 €
Federation Europeenne d'Associations et d'Industries Pharmaceutiques 0,00 €
Fundacion Publica Andaluza Progreso y Salud M.P 270.313 €
Janssen Pharmaceutica N.V. 0,00 €
Merck KGaA 0,00 €
Merck Sharp & Dohme Corp 0,00 €
Novartis Pharma AG 0,00 €
Novo Nordisk A/S 0,00 €
Pfizer Inc. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Takeda Pharmaceuticals International AG 0,00 €
Technische Universitaet Dresden 132.103 €
Teknologian Tutkimuskeskus VTT Oy 519.007 €
Teva Pharmaceutical Industries Ltd. 0,00 €
THE European Association Medical Devices-Notified Bodies 110.625 €
THE European Institute for Innovation Through Health Data 584.063 €
THE European Medicines Agency 197.595 €
Universite Bourgogne Europe 172.169 €
Vlaamse Instelling Voor Technologisch Onderzoek N.V. 1.085.273 €

Quelle: https://cordis.europa.eu/project/id/101219311

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Eli Lilly and Company Ltd., Basingstoke, Großbritannien.